AstraZeneca has sent a legal notice to the Serum Institute of India (SII) for the delay in the supply of the Corona vaccine. SII has therefore sought help from the Government of India in the form of a grant to double the production of Kovsheild. The Serona vaccine, developed by Oxford-AstraZeneca, is made and sold in India with the Covishield brand name in India. SII CEO Adar Poonawala said on Tuesday that about Rs 3,000 crore would be needed to increase the production capacity of the Kovid-19 vaccine.

“We need roughly Rs 3,000 crore, which is not a small figure because we have already spent thousands of crores of rupees,” Poonawalla told a TV channel. We have to find other new ways to build our capacity. ‘ He said that the company expects the production capacity of the Kovishield vaccine to increase…



Read Full Article Here